Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

Roche announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San ...

Roche has a window of opportunity to grow Tecentriq in adjuvant NSCLC unopposed, but it could be short-lived, as Merck now has data in hand for Keytruda in these patients from the KEYNOTE-091 ...

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with Merck ...

The global market for cancer-focused genetic testing services is on a transformative growth trajectory, with projections estimating a market size of USD 8,472.70 million by 2024, and an expected ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

1 Day ROG -1.02% DJIA 0.59% S&P 500 0.38% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Brandon Roche went missing in the water in Wexford Harbour on Saturday, October 26, sparking a 10-day search for his body. The young man's heartbroken mum Samantha and other family members had ...